Abstract 1707
Background
The androgen receptor splice variant 7 (AR-V7) is associated with resistance to hormonal therapy in castration resistant prostate cancer (CRPC). Due to the limitations of methods available for AR-V7 analysis, the identification of a reliable detection method may facilitate the use of this biomarker in clinical practice. In order to provide a reliable laboratory approach to AR-V7 assessment, the present study was conducted to: 1) confirm the role of AR-V7 in prediction of resistance to hormonal therapy; 2) develop a new methodological approach to reliably and easily assess AR-V7 by a digital droplet PCR in exosomal-derived RNA from plasma samples and 3) provide new data to address the correlation between exosomal-derived AR-V7 RNA and resistance, being the translation CTC to exosomes not obvious.
Methods
Two ml of plasma samples were collected from 36 CRPC patients before the beginning of second-line hormonal treatment. Exosomes were isolated and RNA extracted for analysis of AR-V7 by digital droplet PCR.
Results
39% of patients were found carriers of the AR-V7 transcript. Twenty-six patients received abiraterone and 10 enzalutamide. The median clinical or radiographic progression free survival was significantly longer in AR-V7 negative compared to positive patients (20 vs 3 months; P
Conclusions
The present study demonstrates that plasma-derived exosomal RNA is a reliable source of AR-V7 and its detection predicts resistance to anti-hormonal therapy. The method is sensitive, fast and represents a convenient alternative to other potentially more expensive and less sensitive approaches, i.e., circulating tumor cells.
Clinical trial identification
Not applicable
Legal entity responsible for the study
Prof. Romano Danesi
Funding
Academic fundings
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Risk of prostate cancer mortality in men with an initial benign needle core biopsy set: a population based analysis with up to 20 years of follow-up
Presenter: Nina Klemann
Session: Genitourinary tumours, prostate
Resources:
Abstract
PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Genitourinary tumours, prostate
Resources:
Abstract
Presentation
PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Genitourinary tumours, prostate
Resources:
Abstract
Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifer in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial
Presenter: Felix Feng
Session: Genitourinary tumours, prostate
Resources:
Abstract
Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study
Presenter: Aaron Hansen
Session: Genitourinary tumours, prostate
Resources:
Abstract
Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patients
Presenter: Cécile Vicier
Session: Genitourinary tumours, prostate
Resources:
Abstract
Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)
Presenter: Wanling Xie
Session: Genitourinary tumours, prostate
Resources:
Abstract
Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial
Presenter: Christopher Sweeney
Session: Genitourinary tumours, prostate
Resources:
Abstract
Invited discussant abstracts LBA29 and 719O
Presenter: Winald Gerritsen
Session: Genitourinary tumours, prostate
Resources:
Presentation
Invited discussant abstracts 725PD, 726PD, 727PD, 728PD, 729PD and 730PD
Presenter: David Olmos
Session: Genitourinary tumours, prostate
Resources:
Presentation
Webcast